Beam Therapeutics Inc. (BEAM) Financials
BEAM Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 1.5 billion | 478.4 million |
2023-09-30 | 1.3 billion | 511.6 million |
2023-06-30 | 1.4 billion | 542.2 million |
2023-03-31 | 1.3 billion | 570.8 million |
BEAM Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | 131.5 million | 22.6 million |
2023-09-30 | -97.7 million | 25.8 million |
2023-06-30 | -100.8 million | 26.3 million |
2023-03-31 | -115.8 million | 23.9 million |
BEAM Net Income
No data available :(
BEAM Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 1.2 billion | - | 172.7 million |
2023-09-30 | 1.0 billion | - | 172.6 million |
2023-06-30 | 1.1 billion | - | 175.3 million |
2023-03-31 | 1.1 billion | - | 176.5 million |
BEAM Shares Outstanding
BEAM Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | 3.6 million | 140.1 million | 43.3 million | -5.4 million |
2023-09-30 | 7.9 million | 100.1 million | 25.4 million | - |
2023-06-30 | 16.2 million | 97.6 million | 24.7 million | - |
2023-03-31 | 6.0 million | 99.6 million | 23.5 million | - |
BEAM Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | 316.2 million | 5.4 million |
2023-09-30 | 17.2 million | 7.5 million |
2023-06-30 | 20.1 million | 7.3 million |
2023-03-31 | 24.2 million | 7.0 million |
BEAM
Price: $21.74
52 week price:
Payout Ratio Range:
Earnings Per Share: -1.72 USD
P/E Ratio: -6.97
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Volume: 1.0 million
Market Capitalization: 2.2 billion
Average Dividend Frequency: 4